Replies to post #141 on Precision BioSciences Inc (DTIL)

[NY1972]

Response MCL AUTO limited by:
1. T cells fitness and dose of CD8 and CCR71 CD45RA1 T cells too low.
2. High TB
P2 trial of the autologous anti-CD19 chimeric antigen receptor (CAR)
T-cell therapy brexucabtagene autoleucel (KTE-X19) in patients with heavily pretreated MCL. The median DOR was 46.7 months among patients with CR (46/71) and 2.2 months in patients with PR (16/71)
https://ashpublications.org/bloodadvances/article/4/19/4898/464200/Tumor-burden-inflammation-and-product-attributes